Intellia Therapeutics
Clinical trials sponsored by Intellia Therapeutics, explained in plain language.
A gene-editing company using CRISPR technology to develop therapies for genetic diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Gene-Editing shot aims to halt rare nerve disease in phase 3 trial Results expected Jul 2027 (estimated)
-
Gene-Editing shot aims to halt rare nerve disease in phase 3 trial
Disease control Recruiting nowThis phase 3 trial tests a single dose of NTLA-2001, a gene-editing therapy, in 60 adults with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN), a rare genetic disease that damages nerves. Participants are randomly assigned to receive either the active treatmen…
Phase 3 • Sponsor: Intellia Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Gene-Editing breakthrough: could a single dose stop a deadly heart condition?
Disease control Recruiting nowThis study tests a single dose of NTLA-2001, a gene-editing therapy, in 1200 adults with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), a condition where abnormal protein builds up in the heart. The goal is to see if it reduces heart-related deaths and events compared t…
Phase 3 • Sponsor: Intellia Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC